Search results
Results From The WOW.Com Content Network
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024. ... Revenue from COVID products fell to $12.5 billion in 2023, down 78% from the $57 billion of peak in 2022. Analysts expect ...
Pfizer now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior forecast of $2.15 to $2.35. ... Pfizer was disappointed with its 2023 launch of RSV shot ...
Pfizer shares were off less than 1% in midday trading. Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from it prior forecast of $67 billion to $70 billion. It said the reduction was solely due to lowered ...
(November 2023) (Learn how and when ... Pfizer. 8,697 4,009 4 Infliximab: Remicade Biologic Crohn's Disease. Rheumatoid Arthritis. ... a non-profit organization ...
Zoetis Inc. (/zō-EH-tis/ [4]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. [5] [4] [6] The company was a subsidiary of Pfizer, [7] the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.
Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1. ...